268 related articles for article (PubMed ID: 35716286)
1. STAT3 in medulloblastoma: a key transcriptional regulator and potential therapeutic target.
Zaiter A; Audi ZF; Shawraba F; Saker Z; Bahmad HF; Nabha RH; Harati H; Nabha SM
Mol Biol Rep; 2022 Nov; 49(11):10635-10652. PubMed ID: 35716286
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells.
Yu LJ; Wu ML; Li H; Chen XY; Wang Q; Sun Y; Kong QY; Liu J
Neoplasia; 2008 Jul; 10(7):736-44. PubMed ID: 18592012
[TBL] [Abstract][Full Text] [Related]
3. STAT3 is required for Smo-dependent signaling and mediates Smo-targeted treatment resistance and tumorigenesis in Shh medulloblastoma.
Yuan L; Zhang H; Liu J; Malhotra A; Dey A; Yu B; Jella KK; McSwain LF; Schniederjan MJ; MacDonald TJ
Mol Oncol; 2022 Feb; 16(4):1009-1025. PubMed ID: 34482626
[TBL] [Abstract][Full Text] [Related]
4. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.
Wei J; Ma L; Li C; Pierson CR; Finlay JL; Lin J
Curr Cancer Drug Targets; 2019; 19(7):571-582. PubMed ID: 30332965
[TBL] [Abstract][Full Text] [Related]
5. Medulloblastoma stem cells: modeling tumor heterogeneity.
Manoranjan B; Venugopal C; McFarlane N; Doble BW; Dunn SE; Scheinemann K; Singh SK
Cancer Lett; 2013 Sep; 338(1):23-31. PubMed ID: 22796365
[TBL] [Abstract][Full Text] [Related]
6. Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression.
Zagozewski J; Borlase S; Guppy BJ; Coudière-Morrison L; Shahriary GM; Gordon V; Liang L; Cheng S; Porter CJ; Kelley R; Hawkins C; Chan JA; Liang Y; Gong J; Nör C; Saulnier O; Wechsler-Reya RJ; Ramaswamy V; Werbowetski-Ogilvie TE
Commun Biol; 2022 Jul; 5(1):697. PubMed ID: 35835937
[TBL] [Abstract][Full Text] [Related]
7. LLL12B, a small molecule STAT3 inhibitor, induces growth arrest, apoptosis, and enhances cisplatin-mediated cytotoxicity in medulloblastoma cells.
Chen X; Pan L; Wei J; Zhang R; Yang X; Song J; Bai RY; Fu S; Pierson CR; Finlay JL; Li C; Lin J
Sci Rep; 2021 Mar; 11(1):6517. PubMed ID: 33753770
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features of medulloblastoma: an overview with an emphasis on molecular biology.
de Haas TG; Kool M
Clin Neuropathol; 2007; 26(3):93-110. PubMed ID: 19157001
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.
Yang F; Jove V; Xin H; Hedvat M; Van Meter TE; Yu H
Mol Cancer Res; 2010 Jan; 8(1):35-45. PubMed ID: 20053726
[TBL] [Abstract][Full Text] [Related]
10. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells.
Yang MY; Lee HT; Chen CM; Shen CC; Ma HI
Int J Mol Sci; 2014 Jun; 15(6):11013-29. PubMed ID: 24945311
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of SOX2, NOTCH1, and ID1 in supratentorial primitive neuroectodermal tumors: a distinct differentiation pattern from that of medulloblastomas.
Phi JH; Kim JH; Eun KM; Wang KC; Park KH; Choi SA; Kim YY; Park SH; Cho BK; Kim SK
J Neurosurg Pediatr; 2010 Jun; 5(6):608-14. PubMed ID: 20515335
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
Yang F; Van Meter TE; Buettner R; Hedvat M; Liang W; Kowolik CM; Mepani N; Mirosevich J; Nam S; Chen MY; Tye G; Kirschbaum M; Jove R
Mol Cancer Ther; 2008 Nov; 7(11):3519-26. PubMed ID: 19001435
[TBL] [Abstract][Full Text] [Related]
14. Childhood tumors of the nervous system as disorders of normal development.
Grimmer MR; Weiss WA
Curr Opin Pediatr; 2006 Dec; 18(6):634-8. PubMed ID: 17099362
[TBL] [Abstract][Full Text] [Related]
15. Medulloblastoma: from molecular pathology to therapy.
Rossi A; Caracciolo V; Russo G; Reiss K; Giordano A
Clin Cancer Res; 2008 Feb; 14(4):971-6. PubMed ID: 18281528
[TBL] [Abstract][Full Text] [Related]
16. Suppression of STAT3 NH
Ray S; Coulter DW; Gray SD; Sughroue JA; Roychoudhury S; McIntyre EM; Chaturvedi NK; Bhakat KK; Joshi SS; McGuire TR; Sharp JG
Mol Carcinog; 2018 Apr; 57(4):536-548. PubMed ID: 29280516
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation in medulloblastoma pathogenesis revealed by genetically engineered mouse models.
Shiraishi R; Kawauchi D
Cancer Sci; 2021 Aug; 112(8):2948-2957. PubMed ID: 34050694
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of KCASH2 and KCASH3, 2 novel Cullin3 adaptors suppressing histone deacetylase and Hedgehog activity in medulloblastoma.
De Smaele E; Di Marcotullio L; Moretti M; Pelloni M; Occhione MA; Infante P; Cucchi D; Greco A; Pietrosanti L; Todorovic J; Coni S; Canettieri G; Ferretti E; Bei R; Maroder M; Screpanti I; Gulino A
Neoplasia; 2011 Apr; 13(4):374-85. PubMed ID: 21472142
[TBL] [Abstract][Full Text] [Related]
19. Signaling pathway and molecular subgroups of medulloblastoma.
Li KK; Lau KM; Ng HK
Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms and therapeutic targets in pediatric brain tumors.
Liu KW; Pajtler KW; Worst BC; Pfister SM; Wechsler-Reya RJ
Sci Signal; 2017 Mar; 10(470):. PubMed ID: 28292958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
